Drug-drug interaction screening with Omega

library(PVomega)

What Omega measures

Omega (Noren et al. 2008) is a disproportionality measure for drug-drug-event combination. It compares the observed number of reports listing two drugs and an adverse event with the number expected if the two drugs did not interact.

“No interaction” is defined by an additive model: the reporting rate of the event under both drugs is the background reporting rate plus the contribution attributable to each drug. This is the key difference from logistic regression, whose interaction term assumes multiplicative effects of separate drugs and misses well-established interactions such as cerivastatin with gemfibrozil.

The steps are:

  1. Count the reports in each of the four exposure strata: neither drug, D1 only, D2 only, both drugs.
  2. Compute the relative reporting rate of the event in each stratum: f00, f10, f01, f11.
  3. Estimate the expected rate under both drugs, g11, from f00, f10 and f01 only (eq. 16 of the paper).
  4. Compute the expected count E111 = g11 * n11..
  5. Compute the shrunk ratio omega = log2((n111 + 0.5) / (E111 + 0.5)) and its Gamma credibility interval.

A potential interaction is highlighted when omega_lower is above 0.

Starting from counts

omega_from_counts() works with any data source. The example below is the first case study of the paper: delayed bleeding with itraconazole and oral contraceptives.

res <- omega_from_counts(
  n111 = 10, n11. = 23, n1.1 = 10, n.11 = 19,
  n1.. = 39, n.1. = 1489, n..1 = 39, n... = 5503
)
res[, .(f00, f10, f01, f11, g11, E111, omega, omega_lower, omega_upper)]
#>            f00   f10         f01       f11         g11      E111   omega
#>          <num> <num>       <num>     <num>       <num>     <num>   <num>
#> 1: 0.005002501     0 0.006139154 0.4347826 0.006139154 0.1412005 4.03347
#>    omega_lower omega_upper
#>          <num>       <num>
#> 1:    3.003327    4.790041

Starting from a table of counts

omega_from_table() takes a data frame with one row per drug1-drug2-event combination and one column per count (n111, n11., n1.1, n.11, n1.., n.1., n..1, n...). Other columns, such as labels, are kept in the output.

counts <- data.frame(
  drug1 = c("itraconazole", "drug A"),
  drug2 = c("oral contraceptives", "drug B"),
  event = c("delayed bleeding", "event X"),
  n111 = c(10, 45), `n11.` = c(23, 250), `n1.1` = c(10, 120),
  `n.11` = c(19, 85), `n1..` = c(39, 580), `n.1.` = c(1489, 420),
  `n..1` = c(39, 340), `n...` = c(5503, 50000),
  check.names = FALSE
)

Groups of terms can be collapsed with lists, as in DiAna:

res <- omega_from_table(counts)
res[, .(drug1, drug2, event, f11, g11, omega, omega_lower, omega_upper)]

Methodological choices to report

The counts come from your own data, and three choices made when building them change the results. State them in any publication:

Interpreting results

As recommended in the original paper, do not read Omega in isolation. The columns f00, f10, f01 and f11 show why a combination was highlighted. For example, a large f10 means D1 alone already explains much of the reporting.

Omega cannot be estimated when one of the four D1/D2 strata is empty (for example, one drug is never reported without the other), or when every report in the D1-only, D2-only or neither-drug stratum lists the event (f10, f01 or f00 equal to 1). Such rows return NA for g11, E111 and the Omega columns, with a warning that names the affected rows and the reason.

References

Noren et al. 2007

Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Research Report. 2007;2007:6. Mathematical Statistics, Stockholm University.

Noren et al. 2008

Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27(16):3057-70.

Hult et al. 2020

Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43:775-85.